{"product_id":"codx-pestle-analysis","title":"(CODX) Co-Diagnostics, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Co-Diagnostics, Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why they matter for strategy or investment. The page includes a real preview\/sample of the report so you can evaluate style and depth; purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic-health procurement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics’ public-sector sales depend on government buys for PCR testing in clinics, labs, and screening programs. When health ministries fund surveillance, test volumes and reagent orders can jump fast; when budgets shift, they can fall just as fast. That makes policy timing a key driver of quarterly revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-border market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. sells across borders, so export permits, import checks, and local approval rules can delay or speed launches in each country. Political ties also shape access to distributors and public health buyers, which matters when one market can open while another stays closed. For example, EU IVD rules and U.S. FDA pathways can move at different speeds, so cross-border market access is a real launch risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePandemic preparedness spending\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCOVID-19 showed how fast governments can scale budgets; the U.S. alone enacted about $4.6 trillion in pandemic relief by 2022, which helped fund testing and surveillance. Future outbreak-readiness plans can lift demand for Co-Diagnostics, Inc. respiratory, fever, and mosquito-borne disease assays. If preparedness spending eases, near-term test orders and revenue upside would likely shrink.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health surveillance priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic-health surveillance for TB, hepatitis, influenza, malaria, dengue, and Zika supports Co-Diagnostics, Inc.’s test menu; WHO said TB still hit 10.8 million people and caused 1.25 million deaths in 2023, while malaria reached 263 million cases.\u003c\/p\u003e\n\u003cp\u003eThese priorities shift by region and election cycle, so funding can swing fast. Still, when governments keep screening on the books, reagent use tends to repeat.\u003c\/p\u003e\n\u003cp\u003eThat matters for Co-Diagnostics, Inc. because surveillance-led programs can drive steady assay and consumable demand, not just one-off instrument sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTB and malaria keep demand alive.\u003c\/li\u003e\n\u003cli\u003ePolicy changes can delay buying.\u003c\/li\u003e\n\u003cli\u003eStable surveillance boosts reagent pulls.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS biomedical policy environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. is exposed to US healthcare policy from Salt Lake City, Utah, where federal backing for diagnostics, biotech, and domestic manufacturing can lower funding risk and speed scale-up. US agency leadership, especially FDA and NIH signals, also shapes how buyers and regulators abroad judge the platform. In a tighter reimbursement and approval setting, policy support can matter as much as product demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFederal support can aid growth and financing.\u003c\/li\u003e\n\u003cli\u003eFDA credibility can lift global trust.\u003c\/li\u003e\n\u003cli\u003eDomestic manufacturing fits US policy goals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Budgets Could Swing Co-Diagnostics Demand Fast\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. faces political risk from public health budgets, which can swing demand fast. WHO reported 10.8 million TB cases and 263 million malaria cases in 2023, keeping surveillance spending relevant. U.S. policy also matters: about $4.6 trillion in pandemic relief by 2022 helped testing, but future cuts could trim reagent orders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB\u003c\/td\u003e\n\u003ctd\u003e10.8M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria\u003c\/td\u003e\n\u003ctd\u003e263M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. relief\u003c\/td\u003e\n\u003ctd\u003e$4.6T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes how political, economic, social, technological, environmental, and legal forces shape Co-Diagnostics, Inc.’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Co-Diagnostics PESTLE snapshot that simplifies external risk review for faster planning and presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, regulatory filings, and peer-reviewed studies to speed due diligence and validate Co-Diagnostics’ claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic spending cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiagnostic spending at Co-Diagnostics, Inc. rises and falls with healthcare budgets and test volumes; U.S. health spending hit $4.9 trillion in 2023, so funding shifts matter. Reagent sales usually improve when infectious-disease screening is prioritized, but tighter budgets can delay hospital and public-lab orders. In slowdowns, purchase cycles stretch and smaller screening programs are often cut first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReimbursement pressure is a key risk for Co-Diagnostics, Inc. because PCR uptake in point-of-care and home use depends on payer coverage and price. If insurers limit coverage, test volumes can drop fast; if coverage is broad, utilization of the Co-Dx PCR platform can rise. In 2025, payer policy still remained the main gatekeeper for home and near-patient PCR adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-cap capital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. is still a development-stage diagnostics company, so it may need outside capital to fund R and D and push products to market. Small-cap stocks often trade with lower liquidity, so share-price swings can raise dilution risk and lift the cost of new funding. Weak equity markets can shut the door on cheap equity raises, which can slow expansion and delay commercialization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal emerging-market demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEmerging markets support Co-Diagnostics, Inc. because WHO still counts about 249 million malaria cases and 10.8 million TB cases in 2023, plus dengue is rising across Asia and Latin America. These large patient pools can lift test demand, but pricing is tighter than in richer markets.\u003c\/p\u003e\n\u003cp\u003eLower- and middle-income countries often buy at lower average selling prices, so volume matters more than margin. A weaker local currency can also cut reported revenue when sales are translated back into US dollars.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge disease burden supports demand\u003c\/li\u003e\n\u003cli\u003eLower ASPs pressure margins\u003c\/li\u003e\n\u003cli\u003eFX swings can distort reported sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and supply costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eManufacturing and supply costs directly shape Co-Diagnostics, Inc. gross margin because reagents, plastics, instrumentation, and logistics sit in every PCR test kit. Inflation in shipping, labor, and inputs can squeeze profitability fast, so efficient production and tight procurement matter for scalable unit economics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReagents and plastics drive unit cost\u003c\/li\u003e\n\u003cli\u003eShipping and labor inflation raise pressure\u003c\/li\u003e\n\u003cli\u003eScale improves PCR economics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer Rules and Global Demand Still Shape Co-Diagnostics’ Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. is still tied to payer rules: broad coverage lifts PCR use, but tighter reimbursement can slow orders. U.S. health spending reached $4.9 trillion in 2023, so budget pressure still shapes test demand.\u003c\/p\u003e\n\u003cp\u003eEmerging markets help, but lower ASPs and FX swings can cut margins and reported sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. health spend\u003c\/td\u003e\n\u003ctd\u003e$4.9T (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO TB cases\u003c\/td\u003e\n\u003ctd\u003e10.8M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWHO malaria cases\u003c\/td\u003e\n\u003ctd\u003e249M (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eCo-Diagnostics, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Co-Diagnostics, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eThis document covers political, economic, social, technological, legal, and environmental factors with clear insights and implications for investors and managers.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers—what you see is the final file available for immediate download upon checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome-testing acceptance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics is pushing PCR into home and point-of-care use, and adoption depends on whether people feel safe doing a self-test without help. Home testing is now familiar to many users, so comfort with self-administered care can widen demand. Trust in accuracy and simple steps still matters most, since one bad result can slow repeat use and referrals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for rapid answers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and providers want rapid, actionable answers, and PCR testing fits that need because results can guide care in hours, not days. In 2025, faster diagnostics supported earlier isolation for infectious disease and quicker follow-up in cancer workflows. For Co-Diagnostics, Inc., speed matters because delayed results can slow treatment starts and raise downstream care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfectious-disease awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic awareness of respiratory and travel-related infections stayed elevated after COVID-19, and WHO still estimates about 1 billion seasonal influenza infections and 10.8 million TB cases each year. Demand for screening also stays relevant for hepatitis B, with about 254 million chronic infections globally, and for mosquito-borne diseases as travel resumes. That supports Co-Diagnostics, Inc.’s test portfolio, while awareness campaigns can lift testing uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAging and chronic-care populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder adults are a growing test market: the UN says people aged 65+ will reach 771 million in 2024 and keep rising, while WHO says chronic diseases cause 74% of global deaths. That boosts demand for accurate molecular diagnostics and ongoing monitoring, and it supports Co-Diagnostics, Inc.'s move into liquid biopsy for earlier screening and prevention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore aging patients mean more diagnostic use\u003c\/li\u003e\n\u003cli\u003eChronic care lifts monitoring demand\u003c\/li\u003e\n\u003cli\u003eLiquid biopsy fits screening trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGlobal health equity gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe global health equity gap keeps molecular diagnostics out of reach for many low-income markets: WHO says 4.5 billion people lacked full health coverage in 2023. Portable PCR and multiplex testing can help Co-Diagnostics, Inc. reach underserved sites faster, but uptake still depends on low pricing, simple training, and reliable distribution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4.5 billion people lacked full coverage in 2023\u003c\/li\u003e\n\u003cli\u003ePortable PCR fits remote, low-resource care\u003c\/li\u003e\n\u003cli\u003eAffordability and training drive adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgeing Populations Sustain Demand for Fast Molecular Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAdoption of Co-Diagnostics, Inc. depends on trust, simple use, and comfort with self-testing. WHO still estimates about 1 billion seasonal influenza infections and 10.8 million TB cases each year, while the UN says people aged 65+ reached 771 million in 2024. That keeps demand high for fast, easy molecular testing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgeing\u003c\/td\u003e\n\u003ctd\u003e771 million aged 65+ in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfection awareness\u003c\/td\u003e\n\u003ctd\u003e1 billion flu, 10.8 million TB cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Dx PCR platform portability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.'s Co-Dx PCR platform is built to move PCR testing closer to the patient, with point-of-care and home-use formats that can cut reliance on central labs. That matters because faster, local testing can lower turnaround time from days to hours in clinics, pharmacies, and remote sites. Portability also widens use cases where lab access is weak, especially for urgent infectious-disease screening.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiplex reagent design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics designs specialized nucleic-acid reagents for multiplex PCR, letting one run detect several pathogens at once. That matters in respiratory and mosquito panels, where speed and sample savings raise lab throughput and lower per-test handling time.\u003c\/p\u003e\n\u003cp\u003eFor Co-Diagnostics, better multiplex design can improve assay breadth without adding extra runs, which is important in screening workflows that need fast, high-volume triage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroader assay applications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics' platform extends beyond infectious disease into liquid biopsy and agriculture, which can lower reliance on any single test category. That technical flexibility matters in molecular diagnostics, where one assay design can support multiple markets and use cases. It also gives Co-Diagnostics more room to spread risk as demand shifts across disease, oncology, and crop testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAutomation and usability needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s growth depends on automation that works outside central labs, because non-lab settings need simple setup and low-touch workflows. User-friendly hardware and software can cut training time, while reliable automation improves reproducibility and makes it easier to scale testing without adding staff.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSimple workflows matter in non-lab settings\u003c\/li\u003e\n\u003cli\u003eAutomation lowers training needs\u003c\/li\u003e\n\u003cli\u003eReliability supports scale and repeatability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompetitive PCR innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. faces a crowded PCR field with large diagnostics and life-science rivals, so faster cycle times, higher sensitivity, and lower cost per test stay critical. PCR workflows still hinge on about 35 to 45 amplification cycles, so small gains in speed and detection can matter. Continuous product development is key to stay relevant as competitors refresh platforms and assays.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpeed shapes adoption.\u003c\/li\u003e\n\u003cli\u003eSensitivity drives clinical value.\u003c\/li\u003e\n\u003cli\u003eLow test cost protects margin.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFast PCR and Multi-Market Reach Drive Co-Diagnostics’ Edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. depends on faster, lower-touch PCR tech, because non-lab use needs simple setup and quick reads. Multiplex assays can detect several pathogens in one run, and PCR usually needs about 35 to 45 cycles, so speed and sensitivity still drive adoption. Its platform also lowers single-market risk across infectious disease, oncology, and agriculture.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePCR cycles\u003c\/td\u003e\n\u003ctd\u003e35 to 45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse case spread\u003c\/td\u003e\n\u003ctd\u003e3 markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and foreign regulator oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. must clear FDA and foreign regulator reviews before selling diagnostic products, and those rules can shift launch timing and label claims. In 2025, the company still depended on approvals outside the U.S. for market access, so any delay can slow revenue recognition and widen sales gaps. If a regulator adds testing or restricts use, commercialization can stall fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome-use and point-of-care compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHome-use and point-of-care tests face tighter usability and safety rules, so Co-Diagnostics, Inc. must prove that lay users can run the assay correctly. Performance claims have to match clinical validation data, and even small gaps can trigger FDA review delays or label changes. Clear instructions, built-in controls, and lot checks are not optional; they are core compliance items.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. depends on patent and IP protection for its reagent and assay tech, so exclusivity matters to pricing power and margin defense. Strong patents can slow copycat launches and support licensing talks, but any IP challenge can delay commercialization or force weaker terms. In diagnostics, one weak claim can hit the whole product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical data and advertising rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. must keep all diagnostic marketing tied to clinical proof, especially sensitivity and specificity data, because false or overstated claims can create FDA, FTC, and civil risk. In diagnostics, even a 1% wording error can turn a supportable claim into a misleading one if the study design does not match the ad.\u003c\/p\u003e\n\u003cp\u003eThe legal bar is high: the company needs clear, repeatable study data and up-to-date performance figures before it promotes test accuracy. One clean rule: if the claim cannot be backed by a valid clinical report, it should not be used in marketing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse only substantiated performance claims\u003c\/li\u003e\n\u003cli\u003eAnchor ads to clinical study data\u003c\/li\u003e\n\u003cli\u003eDocument sensitivity and specificity\u003c\/li\u003e\n\u003cli\u003eAvoid misleading efficacy wording\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrivacy and data handling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s digital test workflows can handle patient data, so privacy rules like HIPAA and GDPR matter as much as the assay itself. Healthcare was the costliest breach sector in 2025, at about $9.77 million per incident, which raises the bar for secure reporting. Compliance is key when selling to health systems and consumers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient data raises HIPAA and GDPR risk.\u003c\/li\u003e\n\u003cli\u003eDigital reporting needs strong cybersecurity.\u003c\/li\u003e\n\u003cli\u003eBreaches can cost $9.77 million on average.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA Delays and Privacy Risks Could Pressure Co-Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLegal risk for Co-Diagnostics, Inc. centers on FDA clearance, privacy, and IP. Any delay in FDA or foreign approval can push sales, while HIPAA and GDPR raise breach exposure; healthcare breach costs averaged $9.77 million in 2025. Patent disputes can also weaken pricing power and slow launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal area\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivacy\u003c\/td\u003e\n\u003ctd\u003eHIPAA, GDPR\u003c\/td\u003e\n\u003ctd\u003e$9.77m avg breach cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulation\u003c\/td\u003e\n\u003ctd\u003eFDA delays\u003c\/td\u003e\n\u003ctd\u003eSlower launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMosquito-borne disease surveillance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc. develops mosquito screening tests that can flag disease-carrying pathogens before outbreaks spread. WHO says vector-borne diseases cause over 700,000 deaths a year, and climate change is widening mosquito ranges into new regions. That makes surveillance tools more useful for public health agencies and labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClimate-driven outbreak risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWarmer temperatures and shifting rainfall expand mosquito ranges, lifting dengue, Zika, chikungunya, and malaria risk. WHO says about 4.2 billion people live in dengue-risk areas, and malaria caused 263 million cases and 597,000 deaths in 2023, so outbreak pressure can raise demand for Co-Diagnostics, Inc. molecular tests. Climate change therefore pushes the product-market need higher, especially in tropical and border regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab consumables and waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePCR testing depends on single-use plastics, reagents, and packaging, so higher test volumes directly raise recurring lab waste. The World Health Organization says healthcare settings generate about 4.8 kg of waste per hospital bed each day, which shows how fast disposal needs can scale. Sustainability pressure is pushing buyers toward lower-waste workflows and reusable lab formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCold-chain and stability demands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s reagents often need 2°C to 8°C storage, so cold-chain control directly drives freight cost and launch speed. WHO has said up to 50% of vaccines are wasted globally, often from temperature breaks, which shows why stability matters for diagnostic reliability too. Longer shelf life cuts spoilage, lowers replacement spend, and helps reach hot, remote markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2°C to 8°C handling is common\u003c\/li\u003e\n\u003cli\u003eHeat risk raises global shipping cost\u003c\/li\u003e\n\u003cli\u003eLonger shelf life reduces waste\u003c\/li\u003e\n\u003cli\u003eBetter stability expands warm-region reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiosafety and contamination control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHandling infectious samples needs sealed workflows, PPE, and validated decontamination so workers stay safe and false results stay low. In Co-Diagnostics, Inc.’s lab and point-of-care tests, biosafety controls matter because even one cross-contamination event can skew amplification-based results. The firm reported $1.8 million revenue in Q1 2025, so protecting each test run supports quality and margin discipline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eContain samples from receipt to disposal\u003c\/li\u003e\n\u003cli\u003eDecontaminate surfaces and tools\u003c\/li\u003e\n\u003cli\u003eProtect staff and result accuracy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMosquito Disease Risk Rising Boosts Test Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClimate change is lifting mosquito-borne disease risk, which supports demand for Co-Diagnostics, Inc. tests; WHO says 4.2 billion people live in dengue-risk areas and malaria caused 263 million cases in 2023. Cold-chain handling at 2°C to 8°C and single-use lab waste also raise cost and compliance pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDengue risk\u003c\/td\u003e\n\u003ctd\u003e4.2B people\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria 2023\u003c\/td\u003e\n\u003ctd\u003e263M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStorage\u003c\/td\u003e\n\u003ctd\u003e2°C to 8°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234233917705,"sku":"codx-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/codx-pestle-analysis.webp?v=1785715473","url":"https:\/\/dcfanalyst.com\/products\/codx-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}